Navigation Links
Southampton scientists begin Phase II patient trial for new asthma treatment

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

An increase in the frequency of asthma attacks (also known as 'exacerbations') is commonly triggered by cold or flu viruses because the lungs of patients with the condition are unable to mount the strong immune response that normally protects healthy airways.

When the infection spreads from the nose to the lungs it also causes inflammation which leads to such exacerbations.

A successful treatment to prevent virus-triggered asthma exacerbations would reduce the number of asthma patients suffering increased frequency of attacks and subsequently potentially life-threatening deterioration of lung function, thereby greatly reducing emergency admissions to hospital.

Professor Ratko Djukanovic, a clinical respiratory specialist at the University's School of Medicine and Southampton University Hospitals NHS Trust and Director of the Southampton Respiratory Biomedical Research Unit, explains: "When common cold or flu viruses spread from the nose and throat to the chest of asthma patients, they can cause a rapid deterioration in their health. Our scientists in Southampton, led by the team of Professor Donna Davies, have found in laboratory-based tests that the lungs are able to protect themselves when the protein interferon beta is introduced.

"If the drug works as we hope it will, it could significantly improve the quality of life for these patients and lessen the number of patients admitted to hospital. However, it is important to stress that there are a number of stages before the drug could be made available to the public.

"We are particularly pleased to have been joined in this clinical trial by other lead asthma centres in the UK which have similar biomedical research units funded by the National Institute for Health Research."

Over the next 9 - 15 months, asthma patients taking part in the study who visit the Biomedical Research Unit at Southampton General Hospital will be given either interferon beta or a placebo by inhalation, when they develop cold or flu symptoms.

The results will be used to determine if inhaled interferon beta is a viable treatment for virus-triggered asthma symptoms.

Scientists have already established that the drug was well tolerated in an earlier Phase I trial in asthma patients and that anti-viral defences were activated.

Richard Marsden, CEO of Synairgen, comments: "We are delighted to be starting this pivotal study. If these tests are successful it could lead to a new treatment being on the market in four years or so. This is very important research and showcases the best of British clinical science and interaction between industry and academic researchers."

Once the study has begun in Southampton, it will be extended to other clinical trial sites around the UK.


Contact: Sophie Docker
University of Southampton

Related medicine news :

1. Scientists find out why living things are the size they are -- and none other
2. Scientists: Soccer improves health, fitness and social abilities
3. Pan-Asian hub for life scientists to open in Suzhou, China, on Monday, April 6
4. Scientists Find Clues to How the Body Fights Off HIV
5. Caltech scientists uncover structure of key protein in common HIV subgroup
6. Start spreading the news: NYU scientists find therapeutic target to stop cancer metastases
7. Scientists Tweak Subjects Brains to Alter Their Moral Choices
8. Scientists in hot pursuit of first new drug for global killer in 50 years
9. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
10. Anti-obesity drugs unlikely to provide lasting benefit according to scientists
11. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: